MS
MBX

Maven Securities’s MBX Biosciences MBX Stock Holding History

Maven Securities’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,000
Closed -$1.3M – 1054
2024
Q3 		$1.3M Buy
+50,000
New +$1.14M 0.03% 441

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Maven Securities's MBX Position: Q4 2024 in Review

Maven Securities sold out of MBX Biosciences (MBX) in Q4 2024, closing a stake of 50,000 shares — an estimated $1.3M sold.

Maven Securities first reported a position in MBX in Q3 2024 and held it in 1 quarter. The position peaked at $1.3M in Q3 2024. 63 funds tracked by Wall St. Rank hold MBX as of Q4 2024.

  • Maven Securities reported no remaining MBX Biosciences position as of Q4 2024 after selling out during the quarter.
  • Maven Securities sold 50,000 MBX Biosciences shares in Q4 2024, an estimated $1.3M.
  • Maven Securities first reported a position in MBX Biosciences in Q3 2024 and held it in 1 quarter.
  • Maven Securities's MBX Biosciences position peaked at $1.3M in Q3 2024.
  • 63 funds tracked by Wall St. Rank held MBX Biosciences as of Q4 2024.

Based on Maven Securities's 13F filing for Q4 2024, filed 14 Feb 2025.